Gregory Moss Sells 14,223 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) insider Gregory Moss sold 14,223 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $22.83, for a total value of $324,711.09. Following the transaction, the insider directly owned 60,835 shares of the company’s stock, valued at $1,388,863.05. This represents a 18.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Evommune Stock Performance

Evommune stock opened at $19.82 on Wednesday. The firm has a 50 day moving average price of $24.12. The firm has a market cap of $713.95 million and a PE ratio of -2.09. Evommune, Inc. has a 12 month low of $13.89 and a 12 month high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. As a group, sell-side analysts expect that Evommune, Inc. will post -2.83 earnings per share for the current year.

Hedge Funds Weigh In On Evommune

A number of hedge funds have recently modified their holdings of EVMN. EQT Fund Management S.a r.l. acquired a new position in shares of Evommune in the 4th quarter worth approximately $84,395,000. RA Capital Management L.P. acquired a new position in shares of Evommune in the 4th quarter worth approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in shares of Evommune in the 4th quarter worth approximately $32,989,000. Nan Fung Group Holdings Ltd acquired a new position in shares of Evommune in the 4th quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Evommune in the 4th quarter worth approximately $22,408,000.

Analyst Upgrades and Downgrades

A number of analysts have commented on EVMN shares. Oppenheimer started coverage on Evommune in a research report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price objective for the company. Clear Str upgraded Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Evercore reiterated an “outperform” rating and issued a $55.00 price objective on shares of Evommune in a research report on Tuesday, February 10th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 price objective on shares of Evommune in a research report on Friday, April 10th. Finally, Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $49.25.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.